BofA changed the firm’s rating on Surgery Partners (SGRY) to Buy from No Rating with a $28 price target as the firm no longer believes that the stock is trading on deal speculation following June’s report that Surgery rejected a buyout offer from Bain Capital. Noting that the stock is trading at a depressed multiple, the firm cites the strong tailwinds it sees for Ambulatory Surgery Centers for its Buy rating.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGRY:
- Surgery Partners upgraded to Buy from Neutral at BofA
- TD says CMS hospital rules positive for Surgery Partners, negative for HCA
- Positive Outlook for Surgery Partners Amid CMS Regulatory Changes Boosting ASC Opportunities
- Surgery Partners Decides to Remain Independent
- Surgery Partners, Bain Capital conclude discussions